Gastroenterology
Volume 135, Issue 6 , Pages 1877-1891 , December 2008

Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles

  • Michael Camilleri

      Affiliations

    • Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota
    • Corresponding Author InformationAddress requests for reprints to: Michael Camilleri, MD, Mayo Clinic, Charlton 8-110, 200 First Street, SW, Rochester, Minnesota 55905
    • ,
  • Lin Chang

      Affiliations

    • Center for Neurobiology of Stress, David Geffen School of Medicine at UCLA, VAGLAHS, Los Angeles, California

Received 18 June 2008 ,Accepted 4 September 2008.

References 

  1. Coleman NS, Marciani L, Blackshaw E, et al. Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther. 2003;18:1039–1048
  2. Paterson WG, Ford D, Ganguli SC, et al. A novel, oral 5HT3 partial agonist, DDP-733, improves overall response in patients with irritable bowel syndrome and constipation (IBS-C): a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study. Gastroenterology. 2008;134:A546–A547
  3. Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil. 2001;13:465–472
  4. Briejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001;423:71–83
  5. de Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT(4) receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20:99–112
  6. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120:354–360
  7. Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut. 1999;44:682–686
  8. Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 2002;16:1347–1356
  9. Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief (Results of a double-blind, placebo-controlled clinical trial). Digestion. 2003;67:82–89
  10. Camilleri M, Kerstens R, Rykx A, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety and effect on quality of life of prucalopride in severe chronic constipation. N Engl J Med. 2008;358:2344–2354
  11. Dennis D, Palme M, Irwin I, et al. ATI-7505 is a novel, selective 5-HT4 receptor agonist that causes gastrointestinal prokinetic activity in dogs. Gastroenterology. 2004;126:A641
  12. Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil. 2007;19:30–38
  13. Manini ML, McKinzie S, Sweetser S, et al. Dose-related study of the effects of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity, on gastrointestinal and colonic transit in healthy volunteers. Abstract submitted to Neurogastroenterology and Motility Joint International Meeting, November 2008, Lucerne, Switzerland.
  14. Goldberg M, Li Yu-Ping, Garofalo B, et al. In patients with chronic constipation, TD-5108, a selective 5-HT4 agonist with high intrinsic activity, increases bowel movement frequency and the proportion of patients with adequate relief. Late breaking Abstract presented at the Annual Meeting of the American College of Gastroenterology, October 12-17, 2007.
  15. Paterson WG, Springer J, O'Mahony M, et al. A randomized, double-blind, placebo-controlled trial with a novel dual noradrenergic reuptake inhibitor (NARI) and 5-HT3 antagonist: results of a phase II 8-week study in female patients with diarrhea predominant irritable bowel syndrome (D-IBS). Gastroenterology. 2008;134:A50
  16. Gorelick AB, Koshy SS, Hooper FG, et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol. 1998;275:G460–G466
  17. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol. 2003;1:219–228
  18. Chial HJ, Camilleri M, Ferber I, et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol. 2003;1:211–218
  19. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8:159–166
  20. Chial HJ, Camilleri M, Burton D, et al. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol. 2003;284:G130–G137
  21. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(Suppl II):S7–S26
  22. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19–31
  23. Creed F, Fernandes L, Guthrie E, et al. North of England IBS Research Group The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003;124:303–317
  24. Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol. 2004;99:914–920
  25. Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55:1095–1103
  26. Vahedi H, Merat S, Rashidioon A, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther. 2005;22:381–385
  27. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol. 2003;1:219–228
  28. Talley NJ, Kellow JE, Boyce P, et al. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci. 2008;53:108–115
  29. Lembo T, Naliboff BD, Matin K, et al. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain. 2000;87:137–147
  30. Borody TJ, Quigley EM, Phillips SF, et al. Effects of morphine and atropine on motility and transit in the human ileum. Gastroenterology. 1985;89:562–570
  31. Steadman CJ, Phillips SF, Camilleri M, et al. Control of muscle tone in the human colon. Gut. 1992;33:541–546
  32. Delvaux M, Louvel D, Lagier E, et al. The κ agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology. 1999;116:38–45
  33. Delgado-Aros S, Chial HJ, Cremonini F, et al. Effects of asimadoline, a κ-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther. 2003;18:507–514
  34. Delvaux M, Beck A, Jacob J, et al. Effect of asimadoline, a κ opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20:237–246
  35. Szarka LA, Camilleri M, Burton D, et al. Efficacy of on-demand asimadoline, a peripheral κ-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007;5:1268–1275
  36. Mangel AW, Bornstein J, Hamm L, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:239–249
  37. Leventer SM, Kucharik RF, Keogh JC, et al. The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. Am J Gastroenterol. 2004;99:S-279
  38. Leventer SM, Raudibaugh K, Frissora CL, et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther. 2008;27:197–206
  39. Chey WY, Jin HO, Lee MH, et al. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol. 2001;96:1499–1506
  40. Wank SA. Cholecystokinin receptors. Am J Physiol. 1995;269:G628–G646
  41. Fourmy D, Escrieut C, Archer E, et al. Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists. Pharmacol Toxicol. 2002;91:313–320
  42. D'Amato M, Rovati LC. Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders. Expert Opin Investig Drugs. 1997;6:819–836
  43. Meyer BM, Werth BA, Beglinger C, et al. Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet. 1989;2:12–15
  44. Cann PA, Rovati LC, Smart HL, et al. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome (A pilot multicenter clinical study). Ann N Y Acad Sci. 1994;713:449–450
  45. Cremonini F, Camilleri M, McKinzie S, et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol. 2005;100:652–663
  46. D'Amato M, Whorwell PJ, Thompson DG. The efficacy and safety of the CCKA-receptor antagonist dexloxiglumide in IBS. Gut. 1999;45(Suppl V):A258
  47. D'Amato M, Whorwell PJ, Thompson DG, et al. The CCK1 receptor antagonist dexloxiglumide is effective and safe in female patients with constipation predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96(Suppl 1):S317
  48. Pharmabiz.com. Forest to discontinue development in US of dexloxiglumide for irritable bowel syndrome. Pharmabiz.com 2004; October http://www.pharmabiz.com/article/detnews.asp?articleid=18255&sectionid=14Last accessed October 9, 2008.
  49. Forest to discontinue development in the US of dexloxiglumide for irritable bowel syndrome. ImmuneSupport.com http://www.immunesupport.com/library/showarticle.cfm/ID/5027Accessed April 10, 2008.
  50. Whorwell PJ, Pace F, D'Amato M, et al. A phase III, 6-month, double-blind, placebo-controlled, randomized withdrawal trial of the selective CCK-1 antagonist dexloxiglumide in constipation-predominant IBS: the Darwin study. Gastroenterology. 2008;134:A157
  51. Holzer P, Holzer-Petsche U. Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol. 2001;1:583–590
  52. Holzer P, Holzer-Petsche U. Tachykinins in the gut (Part I. Expression, release and motor function). Pharmacol Ther. 1997;73:173–217
  53. Moriarty D, Selve N, Baird AW, et al. Potent NK1 antagonism by SR-140333 reduces rat colonic secretory response to immunocyte activation. Am J Physiol. 2001;280:C852–C858
  54. Onori L, Aggio A, Taddei G, et al. Contribution of NK(2) tachykinin receptors to propulsion in the rabbit distal colon. Am J Physiol. 2000;278:G137–G147
  55. Kakol-Palm D, Brusberg M, Sand E, et al. Role of tachykinin NK(1) and NK(2) receptors in colonic sensitivity and stress-induced defecation in gerbils. Eur J Pharmacol. 2008;582:123–131
  56. Oh-Young L, Manakata J, Naliboff B. A double-blind, parallel group pilot study of the effects o CJ-11974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Gastroenterology. 2000;118:A846
  57. Lordal M, Navalesi G, Theodorsson E, et al. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol. 2001;134:215–223
  58. Houghton LA, Cremonini F, Camilleri M, et al. Effect of the NK3 receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil. 2007;19:732–743
  59. Dukes GE, Dewit OE, Sanger GJ, et al. Lack of effect of the NH3 receptor antagonist, talnetant SB223412, on symptoms of IBS: results of 2 randomized, double-blind, placebo-controlled dose-ranging trials. Gastroenterology. 2007;132:A60
  60. Cid LP, Montrose-Rafizadeh C, Smith DI, et al. Cloning of a putative human voltage-gated chloride channel (CIC-2) cDNA widely expressed in human tissues. Hum Mol Genet. 1995;4:407–413
  61. Catalan M, Cornejo I, Figueroa CD, et al. ClC-2 in guinea pig colon: mRNA, immunolabeling, and functional evidence for surface epithelium localization. Am J Physiol. 2002;283:G1004–G1013
  62. Anonymous. Lubiprostone: RU 0211, SPI 0211. Drugs R D. 2005;6:245–248
  63. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol. 2006;290:G942–G947
  64. Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–177
  65. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25:1351–1361
  66. Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2008;27:685–696
  67. Drossman DA, Chey W, Panas R, et al. Lubiprostone significantly improves symptom relief rates in adults with IBS. Gastroenterology. 2007;132:2586–2587
  68. Currie MG, Fok KF, Kato J, et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A. 1992;89:947–951
  69. Hamra FK, Forte LR, Eber SL, et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci U S A. 1993;90:10464–10468
  70. Giannella RA. Escherichia coli heat-stable enterotoxins, guanylins, and their receptors: what are they and what do they do?. J Lab Clin Med. 1995;125:173–181
  71. Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept. 1999;81:25–39
  72. Currie MG, Kurtz C, Mahajan-Miklos S, et al. Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastroenterol. 2005;100:S328
  73. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133:761–768
  74. Johnston JM, Drossman DA, Lembo A, et al. Linaclotide improves bowel habits and patient reported outcomes in subjects with chronic constipation. Am J Gastroenterol. In press.
  75. Forest Labs. Microbia and Forest Labs announce preliminary results on Linaclotide phase 2B studies. http://www.microbia.com/pdfs/Linaclotide.Phase.2b.03.04.08.FINAL.pdfAccessed October 8, 2008.
  76. Verdu EF, Collins SM. Irritable bowel syndrome and probiotics: from rationale to clinical use. Curr Opin Gastroenterol. 2005;21:697–701
  77. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895–904
  78. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551
  79. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581–1590
  80. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17:687–696
  81. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95:1231–1238
  82. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13:1143–1147
  83. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38(Suppl 6):S104–S106
  84. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26:475–486
  85. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24–33
  86. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome (a double-blind, randomized, placebo-controlled study). Am J Gastroenterol. 2003;98:412–419
  87. Nayak AK, Karnad DR, Abraham P, et al. Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called “chronic amebiasis.”. Indian J Gastroenterol. 1997;16:137–139
  88. Dear KL, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome?. Dig Dis Sci. 2005;50:758–766
  89. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557–563
  90. Lembo A, Zakko SF, Ferreira NL, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short-term treatment leading to long-term sustained response. Gastroenterology. 2008;134:A545
  91. Mayer EA, Bradesi S, Chang L, et al. Functional GI disorders: from animal models to drug development. Gut. 2008;57:384–404
  92. US Department of Health and Human Services FDA Center for Drug Evaluation and Research; US Department of Health and Human Services FDA Center for Biologics Evaluation and Research; US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79
  93. Irvine EJ, Whitehead WE, Chey WD, et al. Design of Treatment Trials Committee Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006;130:1538–1551
  94. Chang L. The trials and tribulations of drug development for functional gastrointestinal disorders. Neurogastroenterol Motil. 2008;20(Suppl 1):130–138
  95. Legro RS, Myers E. Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome. Hum Reprod. 2004;19:1697–1704
  96. Camilleri M, Talley NJ. Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. Neurogastroenterol Motil. 2004;16:135–142
  97. Andresen V, Montori VM, Keller J, et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2008;6:545–555
  98. Heaton KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut. 1992;33:818–824
  99. Horikawa Y, Mieno H, Inoue M, et al. Gastrointestinal motility in patients with irritable bowel syndrome studied by using radiopaque markers. Scand J Gastroenterol. 1999;34:1190–1195
  100. Sadik R, Stotzer PO, Simrén M, et al. Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre. Neurogastroenterol Motil. 2008;20:197–205
  101. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci. 1995;40:86–95
  102. Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008;6:772–781
  103. Hebden JM, Blackshaw E, D'Amato M, et al. Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. Am J Gastroenterol. 2002;97:2315–2320
  104. Chiba T, Kudara N, Sato M, et al. Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil. Hepatogastroenterology. 2005;52:1416–1420
  105. Passaretti S, Guslandi M, Imbimbo BP, et al. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1989;3:267–276
  106. Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther. 2000;14:775–782
  107. Viramontes BE, Camilleri M, McKinzie S, et al. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:2671–2676
  108. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:463–468
  109. Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004;2:895–904
  110. Tack J, Middleton SJ, Horne MC, et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23:1655–1665
  111. Grudell AB, Camilleri M, Jensen KL, et al. Dose-response effect of a β3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am J Physiol. 2008;294:G1114–G1119
  112. Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology. 2000;118:842–848
  113. Chang L, Mayer EA, Labus JS, et al. Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am J Physiol. 2006;291:R277–R284
  114. Schmulson M, Lee OY, Chang L, et al. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol. 1999;94:2929–2935
  115. Zar S, Benson MJ, Kumar D. Rectal afferent hypersensitivity and compliance in irritable bowel syndrome: differences between diarrhoea-predominant and constipation-predominant subgroups. Eur J Gastroenterol Hepatol. 2006;18:151–158
  116. Whitehead WE, Crowell MD, Davidoff AL, et al. Pain from rectal distension in women with irritable bowel syndrome: relationship to sexual abuse. Dig Dis Sci. 1997;42:796–804
  117. Dorn SD, Palsson OS, Thiwan SI, et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut. 2007;56:1202–1209
  118. Dickhaus B, Mayer EA, Firooz N, et al. Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol. 2003;98:135–143
  119. Posserud I, Agerforz P, Ekman R, et al. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut. 2004;53:1102–1108
  120. Caldarella MP, Milano A, Laterza F, et al. Visceral sensitivity and symptoms in patients with constipation- or diarrhea-predominant irritable bowel syndrome (IBS): effect of a low-fat intraduodenal infusion. Am J Gastroenterol. 2005;100:383–389
  121. Simrén M, Agerforz P, Björnsson ES, et al. Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2007;19:20–29
  122. Posserud I, Syrous A, Lindström L, et al. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology. 2007;133:1113–1123
  123. Berman SM, Chang L, Suyenobu B, et al. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist, alosetron. Gastroenterology. 2002;123:969–977
  124. Naliboff BD, Derbyshire SW, Munakata J, et al. Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med. 2001;63:365–375
  125. Kern MK, Shaker R. Cerebral cortical registration of subliminal visceral stimulation. Gastroenterology. 2002;122:290–298
  126. Berman SM, Naliboff BD, Suyenobu B, et al. Reduced brainstem inhibition during anticipated pelvic visceral pain correlates with enhanced brain response to the visceral stimulus in women with irritable bowel syndrome. J Neurosci. 2008;28:349–359
  127. Azpiroz F, Bouin M, Camilleri M, et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil. 2007;19(Suppl 1):62–88
  128. Berman S, Munakata J, Naliboff BD, et al. Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain. 2000;4:157–172
  129. Naliboff BD, Berman S, Chang L, et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology. 2003;124:1738–1747
  130. Wilder-Smith CH, Schindler D, Lovblad K, et al. Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut. 2004;53:1595–1601
  131. Ringel Y, Drossman DA, Leserman JL, et al. Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology. 2008;134:396–404
  132. Naliboff BD, Berman S, Suyenobu B, et al. Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology. 2006;131:352–365
  133. Jarcho JM, Chang L, Berman SM, et al. Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT(3) receptor antagonist: a pilot study. Aliment Pharmacol Ther. 2008;28:344–352
  134. Morgan V, Pickens D, Gautam S, et al. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut. 2005;54:601–607
  135. Lackner JM, Coad ML, Mertz HR, et al. Behaviour cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety. Res Ther. 2006;44:621–638
  136. Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female non-constipated IBS patients. Aliment Pharmacol Ther. 1999;13:1419–1427
  137. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female IBS with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149–1159
  138. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with IBS: a randomised, placebo-controlled trial. Lancet. 2000;355:1035–1040
  139. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant IBS. Arch Intern Med. 2001;161:1733–1740
  140. Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol. 2004;99:2195–2203
  141. Chang L, Ameen VZ, Dukes GE, et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2005;100:115–123
  142. Bradette M, Moennikes H, Carter F, et al. Cilansetron in IBS with diarrhea predominance: efficacy and safety in a 6 month global study. Gastroenterology. 2004;126:A42
  143. Coremans G, Clouse RE, Carter F, et al. Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with IBS with diarrhea predominance. Gastroenterology. 2004;126:A643
  144. Miner P, Stanton DB, Carter F, et al. Cilansetron in IBS with diarrhea predominance (IBS-D): efficacy and safety in a 3-month US study. Am J Gastroenterol. 2004;99:S277
  145. Kellow J, Lee OY, Change FY, et al. An Asia-Pacific, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with IBS. Gut. 2003;52:671–676
  146. Nyhlin H, Bang C, Elsborg J, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with IBS. Scand J Gastroenterol. 2004;39:119–126
  147. Muller-Lissner S, Holtmann G, Rueegg P, et al. Tegaserod is effective in the initial and re-treatment of IBS with constipation. Aliment Pharmacol Ther. 2005;21:11–20
  148. Tack J, Muller-Lissner S, Bytzer P, et al. A randomized controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut. 2005;54:1707–1713
  149. Fried M, Beglinger C, Gilgen Bobalj N, et al. Tegaserod is safe, well-tolerated and effective in the treatment of patients with non-diarrhea IBS. Eur J Gastroenterol Hepatol. 2005;17:421–427
  150. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from IBS-C. Aliment Pharmacol Ther. 2002;16:1877–1888
  151. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in IBS patients with abdominal pain, bloating, and constipation. Aliment Pharmacol Ther. 2001;15:1655–1666
  152. Muller-Lissner S, Koch G, Talley NJ, et al. Subject's global assessment of relief: an appropriate method to assess the impact of treatment on IBS-related symptoms in clinical trials. J Clin Epidemiol. 2004;56:310–316
  153. Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant IBS. Am J Gastroenterol. 2001;96:2662–2670
  154. Lembo AJ, Olden KW, Ameen VZ, et al. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant IBS: analysis of two controlled trials. Clin Gastroenterol Hepatol. 2004;2:675–682
  155. Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol. 2007;102:1709–1719
  156. Niv E, Naftali T, Hallak R, et al. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with IBS. Clin Nutr. 2005;24:925–931
  157. Davis K, Philpott S, Kumar D, et al. Randomised double-blind placebo-controlled trial of aloe vera for IBS. (Gastroenterology 2008;134:A50) Int J Clin Pract. 2006;60:1080–1086
  158. Gonsalkorale WM, Houghton LA, Whorwell PJ. Hypnotherapy in IBS. Am J Gastroenterol. 2002;97:954–961
  159. Fehnel S, Johnston J, Kurtz C, et al. Assessing global change and symptom severity in subjects with IBS: qualitative item testing. Am J Gastroenterol. 2006;101:S483
  160. Gordon S, Ameen V, Bagby B, et al. Validation of IBS global improvement scale. Dig Dis Sci. 2003;48:1317–1323
  161. Bijkerk CJ, de Wit NJ, Muris JWM, et al. Outcome measures in IBS. Am J Gastroenterol. 2003;98:122–127
  162. Camilleri M, Mangel AW, Fehnel SE, et al. Primary end points for IBS trials: a review of performance of endpoints. Clin Gastroenterol Hepatol. 2007;5:534–540
  163. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 2002;16:1171–1185
  164. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395–402
  165. Drossman DA, Li Z, Toner BB, et al. Functional bowel disorders (A multicenter comparison of health status and development of illness severity index). Dig Dis Sci. 1995;40:986–995
  166. Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol. 2005;3:717–725
  167. Whitehead WE, Palsson OS, Levy RL, et al. Reports of “satisfactory relief” by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol. 2006;101:1057–1065
  168. Ameen VZ, Heath AT, Mcsorley D, et al. Global measure of adequate relief predicts clinically important difference in pain and is independent of baseline pain severity in IBS. Gastroenterology. 2007;132:A140
  169. Lackner JM, Jaccard J, Krasner SS, et al. Self-administered cognitive behavior therapy for moderate to severe IBS: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol. 2008;6:899–906
  170. Committee for Proprietary Medicinal Products (CPMP). Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. CPMP/EWP/785/97 http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htmLondon: draft April 25, 2002; final document March 19. 2003. Accessed October 9, 2008.
  171. Corazziari E, Bytzer P, Delvaux M, et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2003;18:569–580
  172. Revicki DA Regulatory Issues and Patient-Reported Outcomes Task Force for the International Society for Quality of Life Research. FDA draft guidance and health-outcomes research. Lancet. 2007;369:540–542
  173. Cleeland CS, Ladinsky JL, Serlin RC, et al. Multidimensional measurement of cancer pain: comparisons of US and Vietnamese patients. J Pain Sympt Manag. 1988;3:23–27
  174. Tan G, Jensen MP, Thornby JI, et al. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004;5:133–137
  175. Choi MG, Camilleri M, O'Brien MD, et al. A pilot study of motility and tone of the left colon in patients with diarrhea due to functional disorders and dysautonomia. Am J Gastroenterol. 1997;92:297–302
  176. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–121
  177. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491
  178. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut. 1999;45(Suppl 2):II37–II42
  179. Spiegel BM, Harris LA, Lucak SL, et al. Measuring IBS patient reported outcomes with a single item numeric rating scale: results from the proof cohort. Gastroenterology. 2008;134:A467
  180. Spiegel B, Strickland A, Naliboff BD, et al. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol. 2008;103:2536–2593
  181. Revicki DA, Cella D, Hays RD, et al. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006;4:70
  182. Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2005;2:CD003460
  183. Coulie B, Szarka LA, Camilleri M, et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology. 2000;119:41–50
  184. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709–1711
  185. Burke LB, Kennedy DL, Miskala PH, et al. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther. 2008;84:281–283

 The authors disclose the following: Dr Camilleri reports consulting for Albireo, Tioga, Dynogen, Axcan, Procter & Gamble, SK Bio-Pharmaceuticals, and Salix. As a consultant with GlaxoSmithKline, he attended a meeting at the FDA in January 2008 regarding end points for irritable bowel syndrome. He has received research grants from Novartis, Theravance, Takeda/Sucampo, Johnson & Johnson, Bristol-Myers Squibb, as well as support for studies in irritable bowel syndrome from National Institutes of Health (RO1-DK-54681). Dr. Chang reports consulting for Albireo, GlaxoSmithKline, Forest, Ironwood, McNeil, Prometheus, Salix, Synergy, Takeda, and Tioga and research grant support from GlaxoSmithKline, Prometheus, Rose Pharma. She also receives funding from the National Institutes of Health for studies in irritable bowel syndrome (RO1 AR46122 and P50 DK64539).

PII: S0016-5085(08)01668-5

doi: 10.1053/j.gastro.2008.09.005

Gastroenterology
Volume 135, Issue 6 , Pages 1877-1891 , December 2008

Article Tools

* Image Usage & Resolution